What is it about?
There have been several reports on different prostate cancer screening tests, which may improve the specificity in the early detection of prostate cancer. Cut-off values of these tests are mainly based on data from USA and Europe and may not be applicable to other races. We conducted this study to evaluate the utility of different screening tests for detecting prostate cancer.
Photo by Bill Oxford on Unsplash
Why is it important?
Prostate cancer is one of the most common malignancies in men and is the second leading cause of cancer death for men in the United States. The use of prostate specific antigen (PSA) has revolutionized the diagnosis of prostate cancer. A total PSA (tPSA) level of 4.0 ng/ml has traditionally been considered as the threshold for prostate biopsy; however, with a PSA level from 4 to 10 ng/ml, positive findings on a prostate biopsy occur in less than 50% of the patients. PSA though highly sensitive, may lack specificity for the detection of the prostate cancer, especially with the intermediate levels of PSA between 4.0 and 10.0 ng/ml.
Read the Original
This page is a summary of: Utility of Prostate Specific Antigen Density and Free to Total Prostate Specific Antigen Ratio for Detecting Prostate Cancer in Iranian Men: A Prospective Study of 187 Cases, Current Urology, January 2010, Karger Publishers, DOI: 10.1159/000253399.
You can read the full text:
The following have contributed to this page